Eli Lilly to Invest $1 Billion in India Manufacturing Push

• Eli Lilly to invest $1B+ in India for drug production.
• Partners with local firms to boost Mounjaro supply.
• Hyderabad hub to manage manufacturing, hiring now.

Eli Lilly has declared its intention to channel more than $1 billion in India to expand production with the local drugmakers. The project is expected to relieve the supply of the most necessary drugs for obesity, diabetes, Alzheimer’s, cancer, and autoimmune diseases, thus becoming a good support for Lilly’s global expansion.

In case the local manufacturing facility is not existing, Lilly is joining hands with Indian contract manufacturers to guarantee the availability of its weight-loss drug Mounjaro which was launched this year and some other medications. India’s role as a center for capability building in the global network was highlighted by Patrik Jonsson, President of Lilly International.

This is the aftermath of a U.S. campaign to nurture home production that came into effect following the imposition of a 100% tariff on imported branded drugs on October . Lilly accepted an investment of $5 billion for a plant in Virginia, as part of a $27 billion U.S. expansion plan.

Also Read: Swan Defence, Samsung Heavy Sign MoU for Shipbuilding

The sales of Mounjaro and Novo Nordisk’s Wegovy have doubled in India, thus the awareness of obesity treatment has also grown in the country which is expected to become the second most obese in the world by 2050. The Indian generic drugmakers are preparing themselves to release less expensive Wegovy alternatives when its primary ingredient, semaglutide, gets out of the patent in 2026.

Moreover, Lilly takes a step further in creating a manufacturing and quality hub in Hyderabad for managing its contract manufacturing network and providing the required technical expertise. Engineers, chemists, and quality control experts can already start applying for this job. This move deepens the Lilly supply chain and she can also plan for rising demand and competition.